

Subject: Consultant Pharmacist Recommendation tools for PDP

With a goal of supporting appropriate Antipsychotic utilization and the use of Nuplazid for its approved indication, Parkinson's Disease Psychosis, consider adopting some of the following recommendations into your practice.

As an additional resource, please see the attached document; "**Points to Consider When Using NUPLAZID® (pimavanserin) 34 mg in a Nursing Facility**" and visit the AME website [here](#), to view "**Parkinson's Disease Psychosis: Best Practices for the Consultant Pharmacist.**"

1. Nuplazid Therapeutic Interchange Request

Based on the resident's past medical history and clinical presentation, please consider evaluating for appropriate antipsychotic utilization to treat PDP.

Current orders:

Proposed change:

Initiate Nuplazid (Pimavanserin) 34mg QD and attempt DC of off-label antipsychotic use.

Nuplazid is the only FDA approved option for Parkinson's disease psychosis based on the ability to improve psychosis without impairing resident's motor function.

2. GDR documentation

This resident currently has an order for Nuplazid (pimavanserin) 34mg QD for Parkinson's Disease Psychosis. Due to the enduring progressive disease, a GDR may not be warranted. Please ensure proper documentation is completed to support clinical contraindication.

3. Initiation of AP for PDP:

This resident has a history of Parkinson's Disease and facility staff has identified clinical presentations of psychosis.

Current symptoms:

Please consider initiating Nuplazid (pimavanserin) 34mg QD for Parkinson's Disease Psychosis.

Nuplazid is the only FDA approved medication for Parkinson's Disease Psychosis based on the ability to improve psychosis without impairing resident's motor function.

Thank you.